drugset / Trial / NCT02774044
Efficacy and Safety of Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates
Phase 2/3
Unknown
900 enrolled
Ramesh K Agarwal
All India Institute of Medical Sciences · collabChacha Nehru Bal Chikitsalya, Delhi · collabGovernment Medical College, Chandigarh · collabInstitute of Child health and Hospital for Children, Chennai · collabJawaharlal Institute of Postgraduate Medical Education & Research · collabKing Edward Memorial Hospital, Mumbai · collabKing Edward Memorial Hospital, Pune · collabLady Hardinge Medical College · collabLokmanya Tilak Municipal General Hospital, Mumbai · collabMaulana Azad Medical College, New Delhi · collabPost Graduate Institute of Medical Education and Research, Chandigarh · collabSt Johns Medical College Hospital, Bangalore, India · collabWellcome Trust · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the study is to evaluate the efficacy and safety of Cadisurf (goat lung surfactant extract) as compared to Survanta (beractant) in the treatment of respiratory distress syndrome in preterm neonates (with gestation of 26 to 32 weeks).
Timeline
- Start
- 2016-06
- Primary completion
- 2019-02
- Completion
- 2019-05
Outcome
Missed primary endpoint
paper There was no significant difference in the primary outcome of death or BPD between GLSE group (n = 52) and beractant group (n = 46) PMID 31485014 ↗
paper The need for repeat dose of surfactant was significantly higher in GLSE group (65.4 vs. 17.4%; OR 9.0; 95% CI 3.5-23.3; p < 0.001). PMID 31485014 ↗